Literature DB >> 15798116

Becoming the Framingham Study 1947-1950.

Gerald M Oppenheimer1.   

Abstract

In the epidemiological imagination, the Framingham Heart Study has attained iconic status, both as the prototype of the cohort study and as a result of its scientific success. When the Public Health Service launched the study in 1947, epidemiological knowledge of coronary heart disease was poor, and epidemiology primarily involved the study of infectious disease. In constructing their investigation, Framingham's initiators had to invent new approaches to epidemiological research. These scientific goals were heavily influenced by the contending institutional and personal interests buffeting the study. The study passed through vicissitudes and stages during its earliest years as its organizers grappled to define its relationship to medicine, epidemiology, and the local community.

Entities:  

Mesh:

Year:  2005        PMID: 15798116      PMCID: PMC1449227          DOI: 10.2105/AJPH.2003.026419

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  18 in total

1.  CORONARY HEART DISEASE AMONG MINNESOTA BUSINESS AND PROFESSIONAL MEN FOLLOWED FIFTEEN YEARS.

Authors:  A KEYS; H L TAYLOR; H BLACKBURN; J BROZEK; J T ANDERSON; E SIMONSON
Journal:  Circulation       Date:  1963-09       Impact factor: 29.690

2.  The Williamson County Tuberculosis Study. A twenty-four-year epidemiologic study.

Authors:  L D ZEIDBERG; R S GASS; A DILLON; R H HUTCHESON
Journal:  Am Rev Respir Dis       Date:  1963-03

3.  Factors of risk in the development of coronary heart disease--six year follow-up experience. The Framingham Study.

Authors:  W B KANNEL; T R DAWBER; A KAGAN; N REVOTSKIE; J STOKES
Journal:  Ann Intern Med       Date:  1961-07       Impact factor: 25.391

4.  Coronary heart disease in the Framingham study.

Authors:  T R DAWBER; F E MOORE; G V MANN
Journal:  Am J Public Health Nations Health       Date:  1957-04

5.  Measuring the risk of coronary heart disease in adult population groups. The clinical status of a population group in Los Angeles under observation for two to three years.

Authors:  J M CHAPMAN; L S GOERKE; W DIXON; D B LOVELAND; E PHILLIPS
Journal:  Am J Public Health Nations Health       Date:  1957-04

6.  Nutrition in relation to the etiology and the course of degenerative diseases.

Authors:  A KEYS
Journal:  J Am Diet Assoc       Date:  1948-04

7.  Heart diseases and allied causes of death in relation to age changes in the population.

Authors:  I M MORIYAMA; M GOVER
Journal:  Public Health Rep       Date:  1948-04-23       Impact factor: 2.792

8.  Diabetes control in a local health department.

Authors:  H L C WILKERSON; M J FORD
Journal:  Am J Public Health Nations Health       Date:  1949-05

9.  The epidemiologic transition. A theory of the epidemiology of population change.

Authors:  A R Omran
Journal:  Milbank Mem Fund Q       Date:  1971-10

10.  Statistical studies of heart diseases; important factors in heart disease mortality trends.

Authors:  T D WOOLSEY; I M MORIYAMA
Journal:  Public Health Rep       Date:  1948-09-24       Impact factor: 2.792

View more
  20 in total

1.  Methods and management: NIH administrators, federal oversight, and the Framingham Heart Study.

Authors:  Sejal S Patel
Journal:  Bull Hist Med       Date:  2012       Impact factor: 1.314

Review 2.  Identifying the appropriate comparison group for HIV-infected individuals.

Authors:  Cherise Wong; Keri Althoff; Stephen J Gange
Journal:  Curr Opin HIV AIDS       Date:  2014-07       Impact factor: 4.283

3.  Balcova heart study: rationale and methodology of the Turkish cohort.

Authors:  Gül Ergör; Ahmet Soysal; Kaan Sözmen; Belgin Ünal; Reyhan Uçku; Bülent Kılıç; Türkan Günay; Alp Ergör; Yücel Demiral; Gül Saatlı; Reci Meseri; Hakan Baydur; Hatice Simşek; Refik Budak; Hale Arık; Nuriye Karakuş
Journal:  Int J Public Health       Date:  2011-10-11       Impact factor: 3.380

4.  Gene expression analysis of whole blood, peripheral blood mononuclear cells, and lymphoblastoid cell lines from the Framingham Heart Study.

Authors:  Roby Joehanes; Andrew D Johnson; Jennifer J Barb; Nalini Raghavachari; Poching Liu; Kimberly A Woodhouse; Christopher J O'Donnell; Peter J Munson; Daniel Levy
Journal:  Physiol Genomics       Date:  2011-11-01       Impact factor: 3.107

5.  Integromic analysis of genetic variation and gene expression identifies networks for cardiovascular disease phenotypes.

Authors:  Chen Yao; Brian H Chen; Roby Joehanes; Burcak Otlu; Xiaoling Zhang; Chunyu Liu; Tianxiao Huan; Oznur Tastan; L Adrienne Cupples; James B Meigs; Caroline S Fox; Jane E Freedman; Paul Courchesne; Christopher J O'Donnell; Peter J Munson; Sunduz Keles; Daniel Levy
Journal:  Circulation       Date:  2014-12-22       Impact factor: 29.690

6.  The CONSTANCES cohort: an open epidemiological laboratory.

Authors:  Marie Zins; Sébastien Bonenfant; Matthieu Carton; Mireille Coeuret-Pellicer; Alice Guéguen; Julie Gourmelen; Mélissa Nachtigal; Anna Ozguler; Ariane Quesnot; Céline Ribet; Grégory Rodrigues; Angel Serrano; Rémi Sitta; Alain Brigand; Joseph Henny; Marcel Goldberg
Journal:  BMC Public Health       Date:  2010-08-12       Impact factor: 3.295

7.  Cohort Profile: The Framingham Heart Study (FHS): overview of milestones in cardiovascular epidemiology.

Authors:  Connie W Tsao; Ramachandran S Vasan
Journal:  Int J Epidemiol       Date:  2015-12       Impact factor: 7.196

Review 8.  70-year legacy of the Framingham Heart Study.

Authors:  Charlotte Andersson; Andrew D Johnson; Emelia J Benjamin; Daniel Levy; Ramachandran S Vasan
Journal:  Nat Rev Cardiol       Date:  2019-11       Impact factor: 32.419

9.  Contributions of the Framingham Heart Study to the Epidemiology of Coronary Heart Disease.

Authors:  George Chen; Daniel Levy
Journal:  JAMA Cardiol       Date:  2016-10-01       Impact factor: 30.154

Review 10.  How did social medicine evolve, and where is it heading?

Authors:  Dorothy Porter
Journal:  PLoS Med       Date:  2006-10       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.